[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1611252T3 - In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren - Google Patents

In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren

Info

Publication number
DK1611252T3
DK1611252T3 DK04723215T DK04723215T DK1611252T3 DK 1611252 T3 DK1611252 T3 DK 1611252T3 DK 04723215 T DK04723215 T DK 04723215T DK 04723215 T DK04723215 T DK 04723215T DK 1611252 T3 DK1611252 T3 DK 1611252T3
Authority
DK
Denmark
Prior art keywords
cell carcinoma
vitro method
transitional cell
bladder
cancer
Prior art date
Application number
DK04723215T
Other languages
English (en)
Inventor
Roman Jose Javier Gomez
Gonzalez Jorge Cuevas
Martinez Antonio Martinez
Buela Laureano Simon
Cruz Simon Santa
Jimenez Maria Saenz
Vila Miguel Molina
Sanchez-Vallejo Corina Junquera
Original Assignee
Progenika Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma Sa filed Critical Progenika Biopharma Sa
Application granted granted Critical
Publication of DK1611252T3 publication Critical patent/DK1611252T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04723215T 2003-03-26 2004-03-25 In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren DK1611252T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200300708 2003-03-26
PCT/EP2004/003219 WO2004085676A1 (en) 2003-03-26 2004-03-25 In vitro method to detect bladder transitional cell carcinoma

Publications (1)

Publication Number Publication Date
DK1611252T3 true DK1611252T3 (da) 2009-11-23

Family

ID=33041266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04723215T DK1611252T3 (da) 2003-03-26 2004-03-25 In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren

Country Status (7)

Country Link
US (1) US8124331B2 (da)
EP (1) EP1611252B1 (da)
AT (1) ATE437963T1 (da)
DE (1) DE602004022266D1 (da)
DK (1) DK1611252T3 (da)
ES (1) ES2330634T3 (da)
WO (1) WO2004085676A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US9089601B2 (en) 2006-07-10 2015-07-28 University Of Rochester Pre- and intra-operative imaging of bladder cancer
ES2323927B1 (es) * 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
KR101830024B1 (ko) 2009-03-25 2018-02-19 제넨테크, 인크. 항-fgfr3 항체 및 그의 사용 방법
EP2877209A1 (en) * 2012-07-27 2015-06-03 Genentech, Inc. Methods of treating fgfr3 related conditions
CA2886002C (en) * 2012-09-27 2020-06-09 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
CN107002141B (zh) * 2014-09-26 2021-11-02 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
WO2018027091A1 (en) 2016-08-05 2018-02-08 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
KR20230052963A (ko) 2020-08-21 2023-04-20 젠자임 코포레이션 Fgfr3 항체 및 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
EP1208231B2 (en) * 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
ATE440869T1 (de) * 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon

Also Published As

Publication number Publication date
WO2004085676A1 (en) 2004-10-07
US20070092878A1 (en) 2007-04-26
EP1611252B1 (en) 2009-07-29
ES2330634T3 (es) 2009-12-14
EP1611252A1 (en) 2006-01-04
US8124331B2 (en) 2012-02-28
ATE437963T1 (de) 2009-08-15
DE602004022266D1 (de) 2009-09-10

Similar Documents

Publication Publication Date Title
Gu et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
Woodcock et al. The treatment of idiopathic pulmonary fibrosis
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
SG10201809111XA (en) The use of inhibitors of bruton's tyrosine kinase (btk)
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
DK1611252T3 (da) In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
MA37777B1 (fr) Préparation pharmaceutique
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
NO20091628L (no) Kombinasjonsmedikament
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs